説明
Sensitivity analysis outcomes from the synbiotic randomized trial are presented, testing robustness of primary findings.
Figure 23
ChartSource Paper
The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant …Cite This Figure
![Figure 23: Sensitivity analysis outcomes from the synbiotic randomized trial are presented, testing robustness of primary findings.]() > Source: Barbara Skrzydło-Radomańska et al. "The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidoba." *Nutrients*, 2020. PMID: [32635661](https://pubmed.ncbi.nlm.nih.gov/32635661/)
<figure> <img src="" alt="Sensitivity analysis outcomes from the synbiotic randomized trial are presented, testing robustness of primary findings." /> <figcaption>Figure 23. Sensitivity analysis outcomes from the synbiotic randomized trial are presented, testing robustness of primary findings.<br> Source: Barbara Skrzydło-Radomańska et al. "The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidoba." <em>Nutrients</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32635661/">32635661</a></figcaption> </figure>
関連するエビデンス
B
Bifidobacterium longum : Irritable Bowel Syndrome (IBS)
B
グレード B · 4 件の研究
Galactooligosaccharides (GOS) : Irritable Bowel Syndrome (IBS)
B
グレード B · 3 件の研究
Lactobacillus acidophilus : Irritable Bowel Syndrome (IBS)
D
グレード B · 3 件の研究
Fructooligosaccharides (FOS) : Irritable Bowel Syndrome (IBS)
グレード D · 2 件の研究